Amphastar Q1 GAAP Net Income Plunges 75% to $6.4M Amidst Gross Margin Decline
AMPH sits 44% above its 52-week low of $17.03.
Summary
Amphastar Pharmaceuticals reported a significant decline in profitability for Q1 2026, with GAAP net income falling 75% to $6.4 million ($0.14 EPS) and adjusted non-GAAP net income decreasing 47% to $19.5 million ($0.42 EPS) compared to the prior year. While net revenues remained largely flat at $171.2 million, gross profit dropped 18% and gross margin compressed from 50.0% to 41.1%. This decline was primarily driven by lower average selling prices for key products like BAQSIMI and Glucagon due to competition and changes in discounts, despite some growth in other product lines and new launches. This material deterioration in profitability is a significant concern for investors.
At the time of this announcement, AMPH was trading at $24.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $17.03 to $31.26. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Access Newswire.